Phase 3 Colorectal Cancer Trial, Recruiting NCT06936774 Sponsor: University Hospital, Basel, Switzerland Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 3 Colorectal Cancer Trial, Recruiting

NCT06936774
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who have rectal cancer in the middle or lower part of the rectum (stages I to IV) and have had a specific type of bowel surgery (called LAR with TME) along with a temporary stoma (an opening in the abdomen to divert waste while the bowel heals)
  • People who are able to understand and agree to take part, confirmed by signing a consent form

Who may not be able to join:

  • People living with dementia or another psychiatric condition that would make it difficult to complete questionnaires or benefit from the training involved in the trial
  • People whose temporary stoma cannot be reversed (closed) because of an ongoing leak at the surgical join or because the cancer has come back in the same area

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Daniel Steinemann, Deputy chief physician, Clarunis - Universitäres Bauchzentrum Basel

Phone: +41 61 777 76 09

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University Hospital, Basel, Switzerland
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
1 May 2028

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Improvement of the LARS score after 13 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov